Form 4: Guardant Health Co-CEO Eltoukhy Sells Shares

Co-Chief Executive Officer Helmy Eltoukhy sold 100,000 shares of Guardant Health common stock on June 5, 2026.

Summary

• Helmy Eltoukhy, Co-CEO of Guardant Health, Inc., executed a series of stock sales totaling 100,000 shares.
• The transactions occurred on June 5, 2026, at weighted average prices ranging from $125.57 to $132.55 per share.
• The shares were held indirectly through the Helmy A. Eltoukhy Revocable Trust.
• Following these transactions, the reporting person retains beneficial ownership of 2,012,919 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be optically negative, it is a routine disclosure of personal financial management by an executive.

Positives

• The sale was executed at a high price point relative to historical trading ranges, reflecting strong recent performance for the issuer.

Negatives

• Insider selling by a Co-CEO can sometimes be perceived by the market as a lack of confidence in near-term upside, though these sales are often pre-planned.

Risks

• Market volatility impacting the value of remaining holdings.
• Potential negative investor sentiment resulting from significant executive divestment.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations or financial performance.

Industry Context

StockSavvy.ai notes that executive selling in the biotech sector is common for liquidity or tax planning purposes and does not necessarily indicate a change in the company's fundamental outlook or strategic direction.

Comparison to Industry Standards

• Executive divestment of this scale is standard practice for long-tenured founders and CEOs in the healthcare and diagnostics industry.
• The transaction volume represents a small fraction of the total outstanding shares, consistent with typical portfolio rebalancing.

Stakeholder Impact

• Shareholders may experience minor price volatility due to the volume of shares sold.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Guardant Health, GH, Insider Trading, Form 4, Helmy Eltoukhy, Biotech, Oncology